Category Press Releases

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s…

Read MoreGilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company’s commitment to going beyond…

Read MoreLilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability,…

Read MoreBoehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas The approval by the National Medical Products Administration (NMPA) in China was based on positive results from the SPRINT Stratum 1 trial sponsored by the National…

Read MoreKoselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis New secondary analysis from Eli Lilly and Company’s (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who…

Read MoreUp to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and…

Read MoreTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer

Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib) plus abiraterone and…

Read MoreUpdate on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer